594 related articles for article (PubMed ID: 21810065)
1. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal vaccination in adults: does it really work?
Pitsiou GG; Kioumis IP
Respir Med; 2011 Dec; 105(12):1776-83. PubMed ID: 21816596
[TBL] [Abstract][Full Text] [Related]
3. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
4. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
5. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
6. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
9. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
10. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?
Borrow R; Heath PT; Siegrist CA
Curr Opin Infect Dis; 2012 Jun; 25(3):292-303. PubMed ID: 22517603
[TBL] [Abstract][Full Text] [Related]
11. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal vaccination in adults: rationale, state of the art and perspectives.
Icardi G; Sticchi L; Bagnasco A; Iudici R; Durando P
J Prev Med Hyg; 2012 Jun; 53(2):78-84. PubMed ID: 23240164
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
14. Decreasing invasive pneumococcal disease in the elderly: a state-level analysis.
McBean AM; Jung K; Hebert PL
Vaccine; 2006 Jul; 24(27-28):5609-14. PubMed ID: 16725240
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
16. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
[TBL] [Abstract][Full Text] [Related]
17. Time for changes in pneumococcal vaccination of adults?
Overman MC
J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S19-22. PubMed ID: 22086890
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
Papadatou I; Spoulou V
Clin Vaccine Immunol; 2016 May; 23(5):388-395. PubMed ID: 27009210
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
